Join Growin Stock Community!

圓祥生技6945.TW Overview

TW StockBiotech. & Medical
(No presentation for 6945)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

圓祥生技（6945）Overall Performance

圓祥生技（6945）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

圓祥生技（6945） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

圓祥生技（6945）Key Information

圓祥生技（6945）Profile

AP Biosciences Inc, a clinical-stage biopharmaceutical company, researches and develops bispecific antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical research phase for treating lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. The company was founded in 2013 and is based in Taipei City, Taiwan.

圓祥生技（6945）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-7.60
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
449.94
PB Ratio
10.85
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-2217.30%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-7.60
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
449.94
PB Ratio
10.85
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-2217.30%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
default symbol

6945

圓祥生技

170.50D

-1.76%

(-0.02)

  • When is 6945's latest earnings report released?

    The most recent financial report for 圓祥生技 (6945) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6945's short-term business performance and financial health. For the latest updates on 6945's earnings releases, visit this page regularly.

  • How much cash does 6945 have?

    At the end of the period, 圓祥生技 (6945) held Total Cash and Cash Equivalents of 1.07B, accounting for 0.73 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is 6945's EPS continuing to grow?

    According to the past four quarterly reports, 圓祥生技 (6945)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.8. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.